Office of Compensation Analysis and Support Program Evaluation Report	Document Number: OCAS-PER-027 Effective Date: 10/31/2007 Revision No. 0			
Clarksville and Medina Site Profile – ORAU TBKS-0039 Page 1 of 1				
Author: <u>Signature on file</u> Date: <u>10/30/</u> Dave Allen, HP Team Leader	2007 Supersedes: None			
Approval: <u>Signature on file</u> Date: <u>10/30/2007</u> J.W. Neton, Associate Director for Science				

RECORD OF ISSUE/REVISIONS			
ISSUE AUTHORIZATION DATE	EFFECTIVE DATE	REV. NO.	DESCRIPTION
10/31/2007	10/31/2007	0	New document to determine which previously completed claims require evaluation for the effect of issuing a revision to the Clarksville TBD.

1.0 <u>Description</u>

The Clarksville Technical Basis Document (ORAUT-TKBS-0039) was issued on 11/14/2006. This document also contained guidance for completing claims from the Medina Base. Prior to issuing the Technical Basis Document (TBD) some claims were completed using information developed for the TBD. Some of that information was modified during the TBD comment resolution process which resulted in an increase in the assigned dose.

2.0 Issue Evaluation

The Clarksville TBD provides prescriptive dose estimates, as well as recommended adjustments to individual dosimetry data. Some of the guidance for the Medina Base is based on parameters developed for the Clarksville plant.

Since the guidance in the TBD is based on prescriptive estimates developed in the TBD, as well as individual dose information, it is not possible to determine which claims are affected by changes made during the TBD comment resolution process.

3.0 Plan for Resolution or Corrective Action

Prior to 11/4/2006, there were 65 Clarksville and Medina claims completed which had a probability of causation below 50%. NIOSH will review these dose reconstructions to determine if the dose assigned in consistent or higher than the issued TBD. NIOSH will provide DOL with the list of 65 claims as well as a determination on each claim as to whether a new Dose Estimate is required. Documentation for each claim not requiring a new dose reconstruction will provide the basis for that determination.